For decades, lipoprotein(a) — often cited as Lp(a) — sat at an uncomfortable intersection in cardiovascular medicine: well-established as a risk factor, but largely untreatable. Statins, the backbone of lipid management, do little to move Lp(a) levels. PCSK9 inhibitors offer a modest reduction of around 20–25%. For the significant portion of the population carrying elevated Lp(a), the clinical options were limited to managing other risk factors and hoping for the best.
That's changing. A new class of RNA-targeting therapies is demonstrating Lp(a) reductions that would have seemed implausible a few years ago. The research sites capable of bringing those therapies across the finish line are more important than ever.
Lp(a) is a lipoprotein particle structurally similar to low-density lipoprotein (LDL) cholesterol, but with an important distinction: it carries an additional protein called apolipoprotein(a), which gives it pro-inflammatory and pro-thrombotic properties that LDL alone does not have. Unlike LDL, Lp(a) levels are approximately 70–90% genetically determined, meaning lifestyle changes to diet and exercise, as well as most lipid-lowering therapies, have minimal impact.
Elevated Lp(a) is an independent and causal risk factor for atherosclerotic cardiovascular disease and calcific aortic valve disease. It promotes atherosclerosis through multiple mechanisms, contributing to plaque formation, pro-inflammatory signaling, and inhibition of fibrinolysis, increasing the risk of blood clots and restricting blood flow to the heart and arteries. It does so regardless of whether other risk factors are controlled. A patient who has achieved target LDL levels and adheres to every lifestyle recommendation can still carry a substantially elevated cardiovascular risk driven entirely by Lp(a).
Importantly, the NLA notes that Lp(a) risk exists on a continuum rather than a simple threshold. Risk rises progressively with increasingly high Lp(a) levels. The 2026 ACC/AHA Dyslipidemia Guidelines put this in concrete terms: an Lp(a) level of 50 mg/dL is associated with an approximately 40% relative increase in ASCVD risk, a level of 100 mg/dL roughly doubles it, and 180 mg/dL increases risk by approximately fourfold — comparable to the risk associated with heterozygous familial hypercholesterolemia.
The NLA recommends Lp(a) be measured at least once in every adult via a simple blood test, a recognition that routine lipid panels are simply not capturing the full picture.
The same genetic determination that makes Lp(a) a reliable risk marker also makes it resistant to standard interventions. Unlike LDL, which responds to statins, fibrates, and dietary change, Lp(a) is largely set at birth. Maintaining a healthy weight and engaging in regular physical activity — interventions that meaningfully reduce high LDL levels, blood pressure, and triglycerides — have minimal effect on Lp(a) levels. What makes this particularly consequential is that it operates as a standalone, independent risk factor rather than an amplifier of existing risk.
The AHA has noted that Lp(a) remains a risk factor for cardiovascular disease even in patients who have successfully lowered their LDL cholesterol. In other words, a patient who appears well-managed by standard lipid metrics may still carry a meaningfully elevated risk that conventional screening would miss entirely.
Biology has long made the case for targeted treatment. Until recently, pharmacology hadn't caught up.
RNA-targeting agents — specifically antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs) — work upstream of the problem, reducing hepatic production of apolipoprotein(a), the structural protein that gives Lp(a) its distinct properties. The results in clinical trials have been notable.
Pelacarsen (Ionis/Novartis), the furthest along in development, is an ASO currently being evaluated in the Phase 3 Lp(a)HORIZON trial, which has enrolled more than 8,300 patients with established cardiovascular disease. Phase 2 data showed it can reduce Lp(a) levels below the 50 mg/dL risk threshold in 98% of participants, approximately an 80% reduction overall. Topline Phase 3 results and regulatory filings are anticipated in 2026.
On the siRNA side, three agents have demonstrated sustained reductions exceeding 90%:
The safety profile across all four agents has been favorable in trials to date, though Phase 3 outcomes will be the definitive test.
Reducing Lp(a) levels is no longer the challenge. The question the field is now racing to answer is whether lowering those levels translates into fewer heart attacks, strokes, and cardiovascular deaths. Those are the kind of hard outcomes data that regulators and payers require before a therapy reaches patients at scale.
That's the mandate driving the current Phase 3 outcomes trials. With enrollment spanning thousands of patients across multiple years, the quality of the clinical research sites executing these studies directly determines the quality of the evidence that emerges.
Lp(a) outcomes trials demand research sites with specific capabilities. Cardiovascular risk stratification, lipid panel expertise, long-term retention strategies, and experience navigating the regulatory complexity of large outcomes studies are all in play. Sites that have operated in the broader lipid space, including trials targeting LDL-C, cholesterol biosynthesis pathways, and cardiovascular endpoints, bring established infrastructure that accelerates site readiness and minimizes trial protocol deviation.
Experience with injectable biologics and familiarity with RNA-based mechanisms of action also carry weight. As these therapies move into later-stage development, sponsors benefit from sites whose teams aren't learning the therapeutic category at the same time they're running the trial.
Remington-Davis has an established track record in lipid and cardiovascular research, including prior experience with LDL-C–targeting therapies. Our team brings the site management capabilities — patient identification, protocol adherence, retention, and regulatory compliance — that complex cardiovascular outcomes trials require.
We also have an upcoming study in the Lp(a) reduction space, making this an area of active and direct relevance to our current operations. We're not building the infrastructure to support this work; it's already in place.
As the Lp(a) therapy landscape advances toward pivotal outcomes data and potential regulatory filings, research site experience will be a differentiator. Sponsors working on pelacarsen, olpasiran, lepodisiran, zerlasiran, or emerging agents in this class are welcome to connect with our team to discuss site qualification and partnership opportunities.
Unlike LDL or blood pressure, Lp(a) operates on its own biological pathway. Its risk contribution persists even in patients who have optimized every other metric. For trial design, this means outcomes signals can be attributed specifically to Lp(a) lowering, not confounded by coincident improvements in other lipid markers.
Current Phase 3 trials — including Lp(a)HORIZON for pelacarsen and OCEAN(a) for olpasiran — are enrolling patients with established ASCVD and elevated Lp(a), typically at or above 70 mg/dL. Patient identification at this level requires sophisticated lipid screening and cardiovascular risk stratification.
Elevated Lp(a) is strongly associated with coronary artery disease, myocardial infarction, and the need for revascularization. This is why current Phase 3 outcomes trials are powered around hard MACE endpoints — coronary heart disease death, myocardial infarction, and urgent revascularization — rather than biomarker reduction alone.
Comorbidities like hypertension, diabetes, kidney disease, and established ASCVD are common in target Lp(a) trial populations. Their presence shapes how studies are powered and how endpoints are interpreted.
Enrollment criteria are narrow, trial durations often span three to five years, and primary endpoints are hard cardiovascular events requiring rigorous adjudication. The RNA-based investigational agents involved are also a relatively novel modality, requiring site staff to be conversant in subcutaneous injection protocols and monitoring requirements that most sites haven't previously encountered.